10-Valent pneumococcal non-typeable <i>H. influenzae</i> protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial.

BMJ Open · 2020 · PMC7252982 · PMID 32448790

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Across remote communities in the NT, surveillance of OM, NP carriage and microbiology of ED from children (mean age ~18 months) with AOMwiP or CSOM showed a trend towards less AOM and less NTHi in ED of children who were vaccinated with PHiD-CV10 compared with PCV7 and non-significant differences in clinical or microbiological outcomes in children vaccinated with PCV13. 2 8 9 These data provide a strong rationale for rigorous evaluation of these vaccines (PHiD-CV10 vs PCV13) on outcomes during the second and third year of life.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.